NEW YORK (GenomeWeb News) - OSI Pharmaceuticals said today that it has expanded a translational research collaboration with AVEO Pharmaceuticals to develop patient-selection biomarkers for cancer therapies under development at OSI.

The partnership, originally announced in 2007, relates to the development of therapies to target epithelial-mesenchymal transition in cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A genome-wide association study highlights a potential role for hair follicles in acne risk, according to New Scientist.

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

In Cell this week: gene editing-based strategy to screen for immune system regulators, ancient plague patterns, and more.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.